Windtree Therapeutics To Report First Quarter 2016 Financial Results And Host Conference Call On Thursday, May 12, 2016
WARRINGTON, Pa., May 3, 2016 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, will report first quarter 2016 financial results and provide business updates on Thursday, May 12, 2016 before the open of the U.S. financial markets.
The Company will also host a live teleconference and webcast, including a slide presentation, at 8:00 a.m. EDT on the same day to discuss the 2016 first quarter financial results along with providing other business updates. The live webcast and archive of the conference call can be accessed at http://windtreetx.investorroom.com/events.
For "listen-only" participants and those who wish to take part in the question and answer portion of the call, dial (877) 870-4263 (domestic) or (412) 317-0790 (international). After placing the call, request to be joined into the Windtree Therapeutics conference call. A replay of the conference call will be accessible one hour after completion through May 19, 2016 by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and referencing conference ID number 10085848.
About Windtree Therapeutics
Windtree Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel surfactant therapies for respiratory diseases and other potential applications. Windtree's proprietary technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and novel drug-delivery technologies being developed to enable noninvasive administration of aerosolized KL4 surfactant. Windtree is focused initially on improving the management of respiratory distress syndrome (RDS) in premature infants and believes that its proprietary technology may make it possible, over time, to develop a pipeline of KL4 surfactant product candidates to address a variety of respiratory diseases for which there are few or no approved therapies.
For more information, please visit the Company's website at www.windtreetx.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/windtree-therapeutics-to-report-first-quarter-2016-financial-results-and-host-conference-call-on-thursday-may-12-2016-300261946.html
SOURCE Windtree Therapeutics, Inc.
